Comparison of Multiple Myeloma and Amyloidosis: Key Differences
Multiple myeloma and amyloidosis are two related, yet distinct, conditions that affect the plasma cells in the bone marrow. While multiple myeloma is a cancer that causes uncontrolled growth of plasma cells, amyloidosis is a disorder characterized by abnormal protein deposits in various tissues.
Common Causes and Risk Factors
Multiple myeloma is primarily caused by genetic mutations and abnormalities in plasma cells, leading to unchecked cell proliferation. Risk factors for multiple myeloma include age (over 60), family history, radiation exposure, and certain chemical exposures.
Amyloidosis, on the other hand, is caused by the accumulation of misfolded amyloid proteins in organs. AL amyloidosis, the most common type, is strongly associated with multiple myeloma or other plasma cell disorders, as it involves the production of abnormal light chains by plasma cells.
Symptoms
Multiple myeloma symptoms include bone pain, especially in the spine or ribs, fatigue and weakness from anemia, frequent infections, hypercalcemia symptoms (nausea, constipation, confusion), kidney dysfunction, and pathological fractures.
Amyloidosis symptoms depend on the organs involved. Common symptoms include fatigue and weight loss, swelling due to heart or kidney issues, heart failure symptoms if cardiac amyloidosis is present, numbness or tingling if nerves are involved, and enlarged tongue or skin changes in some types.
Diagnosis
Diagnosis of multiple myeloma involves blood and urine tests for abnormal proteins, bone marrow biopsy, imaging (X-rays or MRI) to reveal bone lesions, and assessing organ damage using the CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions).
Amyloidosis diagnosis requires a biopsy of affected tissue showing amyloid deposits with Congo red staining, blood and urine tests for light chains, cardiac imaging if heart involvement is suspected, and mass spectrometry to identify amyloid type.
Treatments
Treatments for multiple myeloma aim to slow its progression. This can involve targeted therapies like bortezomib or carfilzomib to kill myeloma cells, immunomodulatory drugs to boost the immune response, stem cell transplant for eligible patients, and supportive care such as pain control and antibiotics for infections.
Amyloidosis treatment focuses on reducing amyloid production. This can involve chemotherapy regimens similar to those for myeloma if AL amyloidosis is present, supportive care for organ dysfunction, and novel agents or stem cell transplant depending on the stage of the disease.
Differences in Progression and Diagnosis
Multiple myeloma typically progresses from precursor stages (MGUS, SMM) with a gradual increase in malignant plasma cells and organ damage. Amyloidosis progression depends on the rate of amyloid deposition and organ involvement, which can cause rapid organ failure, particularly in cardiac amyloidosis.
Diagnosis of myeloma centers on bone marrow and protein abnormalities with imaging showing bone damage, while amyloidosis diagnosis requires tissue biopsy demonstrating amyloid deposits and often relies on cardiac or kidney evaluation if those organs are involved.
Prevalence and Impact
The American Cancer Society estimates that around 32,000 people will receive a diagnosis of multiple myeloma in the United States in 2024. Mortality is significantly worsened when cardiac amyloidosis complicates multiple myeloma, showing higher short-term mortality.
Amyloidosis is a group of rare and serious conditions that also involve the plasma cells. In primary amyloidosis, or AL amyloidosis, plasma cells do not accumulate, but they create abnormal light chains that lead to deposits. These deposits can damage organs and tissues throughout the body and make it difficult for them to function properly.
In summary, multiple myeloma and amyloidosis share a common cause: the presence of malignant plasma cells in the bone marrow. However, they differ in pathological deposits and clinical manifestations. Amyloidosis diagnosis hinges on biopsy-proven amyloid, while myeloma diagnosis depends on plasma cell proliferation and related organ damage. Treatments overlap for AL amyloidosis and myeloma but diverge in managing amyloid-specific organ damage. Progression varies with amyloidosis often causing rapid organ failure, particularly cardiac, which worsens prognosis in myeloma patients.
- Science has led to the discovery that multiple myeloma and amyloidosis are chronic diseases with distinct differences, as the former is a cancer causing uncontrolled growth of plasma cells, while the latter is a set of neurological and skin conditions occurring due to abnormal protein deposits in various tissues.
- In the realm of medical-conditions, there is a strong association between AL amyloidosis and multiple myeloma or other plasma cell disorders, as it involves the production of abnormal light chains by plasma cells.
- Therapies and treatments for multiple myeloma aim to slow its progression, involving targeted therapies like bortezomib or carfilzomib, immunomodulatory drugs, stem cell transplant for eligible patients, and supportive care. On the other hand, for amyloidosis, treatment focuses on reducing amyloid production, relying on chemotherapy regimens, supportive care for organ dysfunction, and novel agents or stem cell transplant, depending on the stage.
- Skin and organ conditions, such as multiple myeloma and certain types of amyloidosis, can significantly impact health-and-wellness when they degrade organs and tissues and lead to rapid organ failure, particularly in the case of cardiac amyloidosis, which worsens the prognosis of multiple myeloma patients.
